LOS ANGELES, CA — (Marketwired) — 02/02/15 — (OTCQB: MMRF) ("MMR"), a leading provider of (PHRs), storage solutions and electronic document management and imaging systems for , today announced that U.S. Patent No. 8,945,550 will issue on February 3, 2015, providing the second U.S. patent, in addition to patents in Australia, Mexico and South Korea, for the Company–s anti-CD20 monoclonal antibody technology. MMR also announced that it is in talks to sell more than 2,000 patient
LOS ANGELES, CA — (Marketwired) — 09/17/14 — (OTCQB: MMRF) ("MMR" or the "Company") today announced that it has received another significant milestone payment pursuant to an existing Non-Exclusive License Agreement (the "Agreement") pertaining to the Company–s biotech assets. Additional information regarding this milestone payment will be contained in the Company–s quarterly report on Form 10-Q for the quarter ending September 30, 2014. The non-exclusive Agre
LOS ANGELES, CA — (Marketwired) — 10/02/13 — (OTCQB: MMRF) ("MMR"), a leading provider of (PHRs), storage solutions and electronic document management and imaging systems for , today announced that two additional patents will be granted for its B-cell vaccine technologies. MMR has been notified it will receive another U.S. patent protecting methods of making compositions for B-cell vaccines pursuant to a Notice of Allowance from the United States Patent and Trademark Office. The
LOS ANGELES, CA — (Marketwired) — 08/26/13 — (OTCQB: MMRF) ("MMR"), a leading provider of (PHRs), storage solutions and electronic document management and imaging systems for , today announced that as a result of the Expedited Patent Allowance Program referred to as the Patent Prosecution Highway ("PPH"), and following the issuance of U.S. patents to MMR for its anti-CD20 monoclonal antibodies, the Company has received confirmation of the filings of a divisional applic
LOS ANGELES, CA — (Marketwired) — 08/19/13 — (OTCQB: MMRF) ("MMR"), a leading provider of (PHRs), storage solutions and electronic document management and imaging systems for , today announced that as a result of China-s participation in the Patent Prosecution Highway Program and the issuance of patents to MMR for its anti-CD20 monoclonal antibodies in the U.S., the Company has received confirmation from China of the filing on August 15, 2013 of a divisional Chinese patent appli
LOS ANGELES, CA — (Marketwired) — 05/28/13 — (OTCQB: MMRF) ("MMR" or the "Company") today announced that Ivor Royston, M.D. has agreed to join the Company-s Board of Directors effective immediately. MMR-s Board of Directors voted unanimously to authorize management of the Company to extend an invitation to Dr. Royston to serve on the Board. MMR-s management and the Board believe it is in the best interest of the Company and its stockholders to have a director whose exper
LOS ANGELES, CA — (Marketwired) — 04/15/13 — (OTCQB: MMRF) ("MMR") today announced that the United States Patent and Trademark Office has issued a Notice of Allowance for the Company-s anti-CD20 monoclonal antibody assets, U.S. Serial No. 11/855,943, under the title, "Antibodies and Methods for Making and Using Them." This is the first U.S. patent to be granted for the Company-s anti-CD20 monoclonal antibodies, which have particular utility in fighting cancers. The anti-
LOS ANGELES, CA — (Marketwire) — 01/28/13 — (OTCQB: MMRF) ("MMR") today announced that the Japan Patent Office has allowed Patent Application No. 2008-529977 directed toward a Method and System for Providing Online Medical Records. The resulting patent will include 40 claims relating to accessing health records through a web site, collecting health records directly from healthcare providers, and managing the records such as by organizing the documents, applying additional password
LOS ANGELES, CA — (Marketwire) — 11/19/12 — (OTCBB: MMRF) today announced that through its wholly owned subsidiary, MMR Life Sciences Group, the Company plans on exploiting its pipeline of biotech assets by facilitating a partnership or other joint venture with a privately held biotech company that has completed its Phase 2 clinical trials and is in the process of beginning Phase 3. The Company has held talks with several privately held biotech companies who are finding it difficult to get
LOS ANGELES, CA — (Marketwire) — 11/28/11 — (OTCBB: MMRF) () today announced that it has just been granted a patent protecting methods of making compositions for B-cell vaccines and will soon also have Notice of Allowance for another U.S. Patent protecting "Methods of treating a patient with a B-cell lymphoma." Although technically complex, the patent is a manufacturing patent that covers the methods of making compositions for B-cell vaccines used in the fight against lymphoma an
